The CDK12 results are striking given an alteration prevalence of 5% to 7% according to the literature and that limited clinical data indicate poor prognosis with minimal benefit from PARP inhibitor monotherapy in patients who have prostate cancer and CDK12 alterations27. This evidence concerns the gene CDK12 and Familial prostate cancer.